Effects of rituximab therapy on B cell differentiation and depletion.
B cells
Flow cytometry
Rituximab
T cells
Journal
Clinical rheumatology
ISSN: 1434-9949
Titre abrégé: Clin Rheumatol
Pays: Germany
ID NLM: 8211469
Informations de publication
Date de publication:
May 2020
May 2020
Historique:
received:
17
12
2019
accepted:
14
02
2020
revised:
08
02
2020
pubmed:
24
2
2020
medline:
2
2
2021
entrez:
24
2
2020
Statut:
ppublish
Résumé
Rituximab is a human/murine chimeric anti-CD20 monoclonal antibody. It is largely used to treat B cell malignancies and has become standard in the management of B cell‑mediated diseases such as rheumatoid arthritis and granulomatosis with polyangitis. The effects of rituximab need to be monitored by B cell phenotyping. Evaluate possible surface markers for monitoring B cell development in response to rituximab treatment. This review discusses the literature on the B cell surface markers analysed by flow cytometry in patients treated with rituximab. A panel of biomarkers of response to treatment to monitor by flow cytometry is also suggested. B cell phenotyping is useful to predict clinical relapses after rituximab treatment. The proposed panel of biomarkers includes CD38
Identifiants
pubmed: 32088800
doi: 10.1007/s10067-020-04996-7
pii: 10.1007/s10067-020-04996-7
doi:
Substances chimiques
Antigens, CD
0
Antirheumatic Agents
0
Biomarkers
0
Rituximab
4F4X42SYQ6
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1415-1421Références
Salles G, Barrett M, Foà R, Maurer J, O'Brien S, Valente N, Wenger M, Maloney DG (2017) Rituximab in B-cell hematologic malignancies: a review of 20 years of clinical experience. Adv Ther 34(10):2232–2273. https://doi.org/10.1007/s12325-017-0612-x
doi: 10.1007/s12325-017-0612-x
pubmed: 28983798
pmcid: 5656728
Pavanello F, Zucca E, Ghielmini M (Feb. 2017) Rituximab: 13 open questions after 20years of clinical use. Cancer Treat Rev 53:38–46. https://doi.org/10.1016/j.ctrv.2016.11.015
doi: 10.1016/j.ctrv.2016.11.015
pubmed: 28056413
Lee I et al (2019) Comparisons of 131I-rituximab treatment responses in patients with aggressive lymphoma and indolent lymphoma. Ann Nucl Med. https://doi.org/10.1007/s12149-019-01401-5
García-Muñoz R et al (2019) Safety of switching from intravenous to subcutaneous rituximab during first-line treatment of patients with non-Hodgkin lymphoma: the Spanish population of the MabRella study. Br J Haematol. https://doi.org/10.1111/bjh.16227
Cylwik B, Gruszewska E, Gindzienska-Sieskiewicz E, Kowal-Bielecka O, Chrostek L (2019) Serum profile of transferrin isoforms in rheumatoid arthritis treated with biological drugs. Clin Biochem. https://doi.org/10.1016/j.clinbiochem.2019.10.005
Fui A et al (2019) Rituximab therapy in interstitial lung disease associated with rheumatoid arthritis. Intern Med J. https://doi.org/10.1111/imj.14306
Geetha D, Kallenberg C, Stone JH, Salama AD, Appel GB, Duna G, Brunetta P, Jayne D (2015) Current therapy of granulomatosis with polyangiitis and microscopic polyangiitis: the role of rituximab. J Nephrol 28:17–27. https://doi.org/10.1007/s40620-014-0135-3
doi: 10.1007/s40620-014-0135-3
pubmed: 25185728
Hill A, Hill QA (2018) Autoimmune hemolytic anemia. Hematology. American Society of Hematology. Educ Program (1):382–389. https://doi.org/10.1182/asheducation-2018.1.382
Cooper N (2017) State of the art – how I manage immune thrombocytopenia. Br J Haematol 177(1):39–54. https://doi.org/10.1111/bjh.14515
doi: 10.1111/bjh.14515
pubmed: 28295192
Jansson AF, Sengler C, Kuemmerle-Deschner J, Gruhn B, Kranz AB, Lehmann H, Kleinert D, Pape L, Girschick HJ, Foeldvari I, Haffner D, Haas JP, Moebius D, Foell D, Peitz J, Grote V (Jan. 2011) B cell depletion for autoimmune diseases in paediatric patients. Clin Rheumatol 30(1):87–97. https://doi.org/10.1007/s10067-010-1630-0
doi: 10.1007/s10067-010-1630-0
pubmed: 21120559
Einarsson JT, Evert M, Geborek P, Saxne T, Lundgren M, Kapetanovic MC (Dec. 2017) Rituximab in clinical practice: dosage, drug adherence, Ig levels, infections, and drug antibodies. Clin Rheumatol 36(12):2743–2750. https://doi.org/10.1007/s10067-017-3848-6
doi: 10.1007/s10067-017-3848-6
pubmed: 28980088
pmcid: 5681601
Mohammed R, Milne A, Kayani K, Ojha U (Feb. 2019) How the discovery of rituximab impacted the treatment of B-cell non-Hodgkin’s lymphomas. J Blood Med 10:71–84. https://doi.org/10.2147/JBM.S190784
doi: 10.2147/JBM.S190784
pubmed: 30881167
pmcid: 6398399
Golay J, Semenzato G, Rambaldi A, Foà R, Gaidano G, Gamba E, Pane F, Pinto A, Specchia G, Zaja F, Regazzi M (Nov. 2013) Lessons for the clinic from rituximab pharmacokinetics and pharmacodynamics. mAbs 5(6):826–837. https://doi.org/10.4161/mabs.26008
doi: 10.4161/mabs.26008
pubmed: 23933992
pmcid: 3896596
Evans R, Salama AD (2014) Update on rituximab: an established treatment for all immune-mediated kidney diseases? Nephron Clin Pract 126(3):97–109. https://doi.org/10.1159/000358887
doi: 10.1159/000358887
pubmed: 24686110
Regazzi MB, Iacona I, Avanzini MA, Arcaini L, Merlini G, Perfetti V, Zaja F, Montagna M, Morra E, Lazzarino M (Dec. 2005) Pharmacokinetic behavior of rituximab: a study of different schedules of administration for heterogeneous clinical settings. Ther Drug Monit 27(6):785–792. https://doi.org/10.1097/01.ftd.0000184162.60197.c1
doi: 10.1097/01.ftd.0000184162.60197.c1
pubmed: 16306856
Rozman S, Grabnar I, Novaković S, Mrhar A, Jezeršek Novaković B (Aug. 2017) Population pharmacokinetics of rituximab in patients with diffuse large B-cell lymphoma and association with clinical outcome. Br J Clin Pharmacol 83(8):1782–1790. https://doi.org/10.1111/bcp.13271
doi: 10.1111/bcp.13271
pubmed: 28239897
pmcid: 5510082
Brezinschek H-P, Rainer F, Brickmann K, Graninger WB (2012) B lymphocyte-typing for prediction of clinical response to rituximab. Arthritis Res Ther 14(4):R161. https://doi.org/10.1186/ar3901
doi: 10.1186/ar3901
pubmed: 22770118
pmcid: 3580553
von Borstel A et al (2019) CD27+CD38hi B cell frequency during remission predicts relapsing disease in granulomatosis with Polyangiitis patients. Front Immunol 10:2221. https://doi.org/10.3389/fimmu.2019.02221
doi: 10.3389/fimmu.2019.02221
Vital EM et al (2011) Reduced-dose rituximab in rheumatoid arthritis: efficacy depends on degree of B cell depletion. Arthritis Rheum 63(3):603–608. https://doi.org/10.1002/art.30152
doi: 10.1002/art.30152
pubmed: 21360489
Vital EM et al (2010) Management of nonresponse to rituximab in rheumatoid arthritis: predictors and outcome of re-treatment. Arthritis Rheum 62(5):1273–1279. https://doi.org/10.1002/art.27359
doi: 10.1002/art.27359
pubmed: 20131284
Edwards JCW et al (2004) Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 350(25):2572–2581. https://doi.org/10.1056/NEJMoa032534
doi: 10.1056/NEJMoa032534
pubmed: 15201414
Jacobi AM et al (Jun. 2008) Activated memory B cell subsets correlate with disease activity in systemic lupus erythematosus: delineation by expression of CD27, IgD, and CD95. Arthritis Rheum 58(6):1762–1773. https://doi.org/10.1002/art.23498
doi: 10.1002/art.23498
pubmed: 18512812
Pike LJ (2003) Lipid rafts: bringing order to chaos. J Lipid Res 44(4):655–667. https://doi.org/10.1194/jlr.R200021-JLR200
doi: 10.1194/jlr.R200021-JLR200
pubmed: 12562849
Wang K, Wei G, Liu D (2012) CD19: a biomarker for B cell development, lymphoma diagnosis and therapy. Exp Hematol Oncol 1(1):36. https://doi.org/10.1186/2162-3619-1-36
doi: 10.1186/2162-3619-1-36
pubmed: 23210908
pmcid: 3520838
Weiner GJ (Apr. 2010) Rituximab: mechanism of action. Semin Hematol 47(2):115–123. https://doi.org/10.1053/j.seminhematol.2010.01.011
doi: 10.1053/j.seminhematol.2010.01.011
pubmed: 20350658
pmcid: 2848172
Florentina P, Binder CJ (2019) Impact of B-cell–targeted therapies on cardiovascular disease. Arterioscler Thromb Vasc Biol 39(9):1705–1714. https://doi.org/10.1161/ATVBAHA.119.311996
doi: 10.1161/ATVBAHA.119.311996
Deans JP, Li H, Polyak MJ (2002) CD20-mediated apoptosis: signalling through lipid rafts. Immunology 107(2):176–182. https://doi.org/10.1046/j.1365-2567.2002.01495.x
doi: 10.1046/j.1365-2567.2002.01495.x
pubmed: 12383196
pmcid: 1782791
Bemark M (2015) Translating transitions – how to decipher peripheral human B cell development. J Biomed Res 29(4):264–284. https://doi.org/10.7555/JBR.29.20150035
doi: 10.7555/JBR.29.20150035
pubmed: 26243514
pmcid: 4547376
Sims GP, Ettinger R, Shirota Y, Yarboro CH, Illei GG, Lipsky PE (2005) Identification and characterization of circulating human transitional B cells. Blood 105(11):4390–4398. https://doi.org/10.1182/blood-2004-11-4284
doi: 10.1182/blood-2004-11-4284
pubmed: 15701725
pmcid: 1895038
Rezvani AR, Maloney DG (Jun. 2011) Rituximab Resistance. Best Pract Res Clin Haematol 24(2):203–216. https://doi.org/10.1016/j.beha.2011.02.009
doi: 10.1016/j.beha.2011.02.009
pubmed: 21658619
pmcid: 3113665
Bonavida B (2014) Postulated mechanisms of resistance of B-NHL to rituximab treatment regimens: strategies to overcome resistance. Semin Oncol 41(5):667–677. https://doi.org/10.1053/j.seminoncol.2014.08.006
doi: 10.1053/j.seminoncol.2014.08.006
pubmed: 25440611
pmcid: 4254685
Qian Y, Ke Q, Wang Z, Zhang B (2015) Regulation of IgD expression and its role in B cell transformation. Blood 126(23):2230–2230. https://doi.org/10.1182/blood.V126.23.2230.2230
doi: 10.1182/blood.V126.23.2230.2230
Ramwadhdoebe TH et al (2019) Effect of rituximab treatment on T and B cell subsets in lymph node biopsies of patients with rheumatoid arthritis. Rheumatol Oxf Engl 58(6):1075–1085. https://doi.org/10.1093/rheumatology/key428
doi: 10.1093/rheumatology/key428
Dass S, Rawstron AC, Vital EM, Henshaw K, McGonagle D, Emery P (Oct. 2008) Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis. Arthritis Rheum 58(10):2993–2999. https://doi.org/10.1002/art.23902
doi: 10.1002/art.23902
pubmed: 18821683
Grigoriadou S, Chowdhury F, Pontarini E, Tappuni A, Bowman SJ, Bombardieri M (2019) B cell depletion with rituximab in the treatment of primary Sjögren’s syndrome: what have we learnt? Clin Exp Rheumatol 37 Suppl 118(3):217–224
pubmed: 31464681
Gomez Mendez LM et al (2018) Peripheral blood B cell depletion after rituximab and complete response in lupus nephritis. Clin J Am Soc Nephrol 13(10):1502–1509. https://doi.org/10.2215/CJN.01070118
doi: 10.2215/CJN.01070118
pubmed: 30089664
pmcid: 6218830
Memon AB et al (2018) Long-term safety of rituximab induced peripheral B-cell depletion in autoimmune neurological diseases. PLoS One 13(1):e0190425. https://doi.org/10.1371/journal.pone.0190425
doi: 10.1371/journal.pone.0190425
pubmed: 29309416
pmcid: 5757948
Hamblin TJ (2003) CD38: what is it there for? Blood 102(6):1939–1940. https://doi.org/10.1182/blood-2003-07-2332
doi: 10.1182/blood-2003-07-2332
Robak T, Błoński J, Skotnicki AB, Piotrowska M, Wróbel T, Rybka J, Kłoczko J, Bołkun Ł, Budziszewska BK, Walczak U, Uss A, Fidecka M, Smolewski P (2018) Rituximab, cladribine, and cyclophosphamide (RCC) induction with rituximab maintenance in chronic lymphocytic leukemia: PALG - CLL4 (ML21283) trial. Eur J Haematol 100(5):465–474. https://doi.org/10.1111/ejh.13042
doi: 10.1111/ejh.13042
pubmed: 29427355
Agematsu K (2000) Memory B cells and CD27. Histol Histopathol 15(2):573–576. https://doi.org/10.14670/HH-15.573
doi: 10.14670/HH-15.573
pubmed: 10809378
Sellam J et al (2011) Blood memory B cells are disturbed and predict the response to rituximab in patients with rheumatoid arthritis. Arthritis Rheum 63(12):3692–3701. https://doi.org/10.1002/art.30599
doi: 10.1002/art.30599
pubmed: 22127692
Roll P, Palanichamy A, Kneitz C, Dorner T, Tony H-P (2006) Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis. Arthritis Rheum 54(8):2377–2386. https://doi.org/10.1002/art.22019
doi: 10.1002/art.22019
pubmed: 16869000
Wu Y-CB, Kipling D, Dunn-Walters DK (2011) The relationship between CD27 negative and positive B cell populations in human peripheral blood. Front Immunol 2:81. https://doi.org/10.3389/fimmu.2011.00081
doi: 10.3389/fimmu.2011.00081
pubmed: 22566870
pmcid: 3341955
Anolik JH, Looney RJ, Lund FE, Randall TD, Sanz I (2009) Insights into the heterogeneity of human B cells: diverse functions, roles in autoimmunity, and use as therapeutic targets. Immunol Res 45(2–3):144–158. https://doi.org/10.1007/s12026-009-8096-7
doi: 10.1007/s12026-009-8096-7
pubmed: 19350211
Sanz I, Wei C, Lee FE-H, Anolik J (2008) Phenotypic and functional heterogeneity of human memory B cells. Semin Immunol 20(1):67–82. https://doi.org/10.1016/j.smim.2007.12.006
doi: 10.1016/j.smim.2007.12.006
pubmed: 18258454
pmcid: 2440717
Möller B et al (2009) Class-switched B cells display response to therapeutic B-cell depletion in rheumatoid arthritis. Arthritis Res Ther 11(3):R62. https://doi.org/10.1186/ar2686
doi: 10.1186/ar2686
pubmed: 19419560
pmcid: 2714106
Rehnberg M, Amu S, Tarkowski A, Bokarewa MI, Brisslert M (2009) Short- and long-term effects of anti-CD20 treatment on B cell ontogeny in bone marrow of patients with rheumatoid arthritis. Arthritis Res Ther 11(4):R123. https://doi.org/10.1186/ar2789
doi: 10.1186/ar2789
pubmed: 19686595
pmcid: 2745807
Bensalem A et al (2019) CD4+ count-dependent concentration-effect relationship of rituximab in rheumatoid arthritis. Br J Clin Pharmacol. https://doi.org/10.1111/bcp.14102
Schwaneck EC et al (2019) T cells, natural killer cells, and γδT cells in a large patient cohort with rheumatoid arthritis: influence of age and anti-rheumatic therapy. Scand J Rheumatol:1–5. https://doi.org/10.1080/03009742.2019.1634755
Vallerskog T et al (2007) Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE. Clin Immunol Orlando Fla 122(1):62–74. https://doi.org/10.1016/j.clim.2006.08.016
doi: 10.1016/j.clim.2006.08.016
Vigna-Perez M et al (2006) Clinical and immunological effects of Rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study. Arthritis Res Ther 8(3):R83. https://doi.org/10.1186/ar1954
doi: 10.1186/ar1954
pubmed: 16677395
pmcid: 1526618
Gunnarsson I, Sundelin B, Jónsdóttir T, Jacobson SH, Henriksson EW, van Vollenhoven RF (2007) Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis. Arthritis Rheum 56(4):1263–1272. https://doi.org/10.1002/art.22505
doi: 10.1002/art.22505
pubmed: 17393458
Sfikakis PP et al (2005) Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial. Arthritis Rheum 52(2):501–513. https://doi.org/10.1002/art.20858
doi: 10.1002/art.20858
pubmed: 15693003
Antonopoulos I, Daoussis D, Lalioti ME, Markatseli TE, Drosos AA, Taraviras S, Andonopoulos AP, Liossis SC (2019) B cell depletion treatment decreases CD4+IL4+ and CD4+CD40L+ T cells in patients with systemic sclerosis. Rheumatol Int 39(11):1889–1898. https://doi.org/10.1007/s00296-019-04350-4
doi: 10.1007/s00296-019-04350-4
pubmed: 31227855
Mauri C, Blair PA (2010) Regulatory B cells in autoimmunity: developments and controversies. Nat Rev Rheumatol 6(11):636–643. https://doi.org/10.1038/nrrheum.2010.140
doi: 10.1038/nrrheum.2010.140
pubmed: 20856268
Rosser EC, Mauri C (2015) Regulatory B cells: origin, phenotype, and function. Immunity 42(4):607–612. https://doi.org/10.1016/j.immuni.2015.04.005
doi: 10.1016/j.immuni.2015.04.005
pubmed: 25902480
Boulassel M-R, al Qarni Z, Burney I, Khan H, al-Zubaidi A, al Naamani A, al-Hinai H, al-Badi A, Qureshi RN, Panjwani V, al Farsi K (Dec. 2018) Levels of regulatory T cells and invariant natural killer cells and their associations with regulatory B cells in patients with non-Hodgkin lymphoma. Mol Clin Oncol 9(6):677–682. https://doi.org/10.3892/mco.2018.1732
doi: 10.3892/mco.2018.1732
pubmed: 30546901
pmcid: 6256168
Quan C et al (2015) The immune balance between memory and regulatory B cells in NMO and the changes of the balance after methylprednisolone or rituximab therapy. J Neuroimmunol 282:45–53. https://doi.org/10.1016/j.jneuroim.2015.03.016
doi: 10.1016/j.jneuroim.2015.03.016
pubmed: 25903728
Gudbrandsdottir S, Brimnes M, Køllgaard T, Hasselbalch HC, Nielsen CH (2018) Effects of rituximab and dexamethasone on regulatory and proinflammatory B-cell subsets in patients with primary immune thrombocytopenia. Eur J Haematol 100(1):45–52. https://doi.org/10.1111/ejh.12978
doi: 10.1111/ejh.12978
pubmed: 28960473
Jing S, Lu J, Song J, Luo S, Zhou L, Quan C, Xi J, Zhao C (2019) Effect of low-dose rituximab treatment on T- and B-cell lymphocyte imbalance in refractory myasthenia gravis. J Neuroimmunol 332:216–223. https://doi.org/10.1016/j.jneuroim.2019.05.004
doi: 10.1016/j.jneuroim.2019.05.004
pubmed: 31100692
Lucchini E, Zaja F, Bussel J (2019) Rituximab in the treatment of immune thrombocytopenia: what is the role of this agent in 2019? Haematologica 104(6):1124–1135. https://doi.org/10.3324/haematol.2019.218883
doi: 10.3324/haematol.2019.218883
pubmed: 31126963
pmcid: 6545833